Latest news
25 items- SECSEC Form 15-12G filed by 2seventy bio Inc.15-12G - 2seventy bio, Inc. (0001860782) (Filer)
- INSIDERDirector Glickman Sarah Js returned 12,050 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - 2seventy bio, Inc. (0001860782) (Issuer)
- INSIDERSEC Form 4 filed by Director Casdin Capital, Llc4 - 2seventy bio, Inc. (0001860782) (Issuer)
- INSIDERDirector Leschly Nick returned 335,964 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - 2seventy bio, Inc. (0001860782) (Issuer)
- INSIDERChief Financial Officer Eatwell Victoria returned 401,111 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - 2seventy bio, Inc. (0001860782) (Issuer)
- INSIDERChief Operating Officer Snow Jessica returned 247,230 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - 2seventy bio, Inc. (0001860782) (Issuer)
- INSIDERDirector Wei Lin returned 17,583 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - 2seventy bio, Inc. (0001860782) (Issuer)
- INSIDERDirector Maus Marcela V. returned 12,050 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - 2seventy bio, Inc. (0001860782) (Issuer)
- INSIDERDirector Newton Charles W. returned 17,092 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - 2seventy bio, Inc. (0001860782) (Issuer)
- INSIDERDirector Torres Denice returned 12,050 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - 2seventy bio, Inc. (0001860782) (Issuer)
- INSIDERPresident and CEO Baird William D Iii returned 1,002,825 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - 2seventy bio, Inc. (0001860782) (Issuer)
- SECSEC Form EFFECT filed by 2seventy bio Inc.EFFECT - 2seventy bio, Inc. (0001860782) (Filer)
- SECSEC Form POS AM filed by 2seventy bio Inc.POS AM - 2seventy bio, Inc. (0001860782) (Filer)
- SECSEC Form S-8 POS filed by 2seventy bio Inc.S-8 POS - 2seventy bio, Inc. (0001860782) (Filer)
- SECSEC Form S-8 POS filed by 2seventy bio Inc.S-8 POS - 2seventy bio, Inc. (0001860782) (Filer)
- SECSEC Form S-8 POS filed by 2seventy bio Inc.S-8 POS - 2seventy bio, Inc. (0001860782) (Filer)
- SECSEC Form S-8 POS filed by 2seventy bio Inc.S-8 POS - 2seventy bio, Inc. (0001860782) (Filer)
- SEC2seventy bio Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Completion of Acquisition or Disposition of Assets, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update, Financial Statements and Exhibits8-K - 2seventy bio, Inc. (0001860782) (Filer)
- SECSEC Form 25-NSE filed by 2seventy bio Inc.25-NSE - 2seventy bio, Inc. (0001860782) (Subject)
- SECAmendment: SEC Form SC 14D9/A filed by 2seventy bio Inc.SC 14D9/A - 2seventy bio, Inc. (0001860782) (Subject)
- SECAmendment: SEC Form SC TO-T/A filed by 2seventy bio Inc.SC TO-T/A - 2seventy bio, Inc. (0001860782) (Subject)
- SECSEC Form 10-Q filed by 2seventy bio Inc.10-Q - 2seventy bio, Inc. (0001860782) (Filer)
- SEC2seventy bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - 2seventy bio, Inc. (0001860782) (Filer)
- PR2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers SquibbAcquisition by Bristol Myers Squibb on track to close in the second quarter of 2025: HSR waiting period expired on May 2, 2025; tender offer expected to expire on May 13, 2025 Abecma generated $59 million U.S. commercial revenue in the first quarter of 2025 Ended quarter with approximately $173 million in cash, cash equivalents, and marketable securities 2seventy bio, Inc. (NASDAQ:TSVT), today reported financial results and recent highlights for the first quarter ended March 31, 2025. "We started 2seventy with a singular focus on harnessing the power of cell therapy to deliver more time for people living with cancer," said Chip Baird, chief executive officer, 2seventy bio. "Over the pas
- SECAmendment: SEC Form SC TO-T/A filed by 2seventy bio Inc.SC TO-T/A - 2seventy bio, Inc. (0001860782) (Subject)
TSVT FAQ
6 questionsWhat does 2seventy bio Inc. do?
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts. 2seventy bio, Inc.(NasdaqGS:TSVT.V) operates independently of bluebird bio, Inc. as of November 4, 2021.Where does TSVT stock trade?
2seventy bio Inc. (TSVT) is listed on NASDAQ.What sector and industry is TSVT in?
2seventy bio Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about TSVT?
2seventy bio Inc. has had 8 recent analyst actions on file. The most recent action was from Goldman: Sell with a $200.00 price target on 2024-06-06.What companies are similar to TSVT?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare TSVT side-by-side with any of them on Quantisnow.How can I track TSVT on Quantisnow?
Quantisnow aggregates 2seventy bio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TSVT to receive live email and push alerts on every new disclosure.